Coronary artery bypass graft surgery up-regulates genes involved in platelet aggregation

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 4, 2012, Pages 557-563

  Reilly, S J ^a   Li, N ^b   Liska, J ^b   Ekstrom M ^b   Tornvall, P ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cyclooxygenase 1; Gene expression; Glycoprotein IIb IIIa receptor; Inflammation; Platelets; Thrombosis

Indexed keywords

CELL ADHESION MOLECULE; CYCLOOXYGENASE 1; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; MESSENGER RNA; PROTHROMBIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY BYPASS GRAFT; FEMALE; FLOW CYTOMETRY; GENE CONTROL; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; UPREGULATION;

AGED; AGED, 80 AND OVER; ANTIGENS, CD31; BLOOD PLATELETS; CORONARY ARTERY BYPASS; CYCLOOXYGENASE 1; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; INTEGRIN ALPHA2; INTEGRIN BETA3; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RISK ASSESSMENT; RISK FACTORS; RNA, MESSENGER; SWEDEN; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 84859175878     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04660.x     Document Type: Article

References (43)

1. Yau JM, Alexander JH, Hafley G, Mahaffey KW, Mack MJ, Kouchoukos N, Goyal A, Peterson ED, Gibson CM, Califf RM, Harrington RA, Ferguson TB. Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from project of ex-vivo Vein graft engineering via transfection [prevent] IV). Am J Cardiol 2008; 102: 546-51.
2. Goldman L, Caldera DL, Nussbaum SR, Southwick FS, Krogstad D, Murray B, Burke DS, O'Malley TA, Goroll AH, Caplan CH, Nolan J, Carabello B, Slater EE. Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med 1977; 297: 845-50.
3. Devereaux PJ, Goldman L, Cook DJ, Gilbert K, Leslie K, Guyatt GH. Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk. CMAJ 2005; 173: 627-34.
4. Devereaux PJ, Goldman L, Yusuf S, Gilbert K, Leslie K, Guyatt GH. Surveillance and prevention of major perioperative ischemic cardiac events in patients undergoing noncardiac surgery: a review. CMAJ 2005; 173: 779-88.
5. Badner NH, Knill RL, Brown JE, Novick TV, Gelb AW. Myocardial infarction after noncardiac surgery. Anesthesiology 1998; 88: 572-8.
6. Fleischmann KE, Goldman L, Young B, Lee TH. Association between cardiac and noncardiac complications in patients undergoing noncardiac surgery: outcomes and effects on length of stay. Am J Med 2003; 115: 515-20.
7. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-71.
8. Schillinger M, Domanovits H, Bayegan K, Holzenbein T, Grabenwoger M, Thoenissen J, Roggla M, Mullner M. C-reactive protein and mortality in patients with acute aortic disease. Intensive Care Med 2002; 28: 740-5.
9. Rosenfeld BA, Beattie C, Christopherson R, Norris EJ, Frank SM, Breslow MJ, Rock P, Parker SD, Gottlieb SO, Perler BA, Melville Williams G, Seidler A, Bell W. The effects of different anesthetic regimens on fibrinolysis and the development of postoperative arterial thrombosis. Perioperative ischemia randomized anesthesia trial study group. Anesthesiology 1993; 79: 435-43.
10. Yousuf O, Bhatt DL. The evolution of antiplatelet therapy in cardiovascular disease. Nat Rev Cardiol 2011; 8: 547-59.
11. Rinder CS, Bonan JL, Rinder HM, Mathew J, Hines R, Smith BR. Cardiopulmonary bypass induces leukocyte-platelet adhesion. Blood 1992; 79: 1201-5.
12. Li N, Astudillo R, Ivert T, Hjemdahl P. Biphasic pro-thrombotic and inflammatory responses after coronary artery bypass surgery. J Thromb Haemost 2003; 1: 470-6.
13. Fabre JE, Gurney ME. Limitations of current therapies to prevent thrombosis: a need for novel strategies. Mol BioSyst 2010; 6: 305-15.
14. Savi P, Labouret C, Delesque N, Guette F, Lupker J, Herbert JM. P2y(12), a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun 2001; 283: 379-83.
15. Bednar F, Osmancik P, Hlavicka J, Jedlickova V, Paluch Z, Vanek T. Aspirin is insufficient in inhibition of platelet aggregation and thromboxane formation early after coronary artery bypass surgery. J Thromb Thrombolysis 2009; 27: 394-9.
16. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, Costa MA. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49: 1505-16.
17. Gnatenko DV, Dunn JJ, McCorkle SR, Weissmann D, Perrotta PL, Bahou WF. Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood 2003; 101: 2285-93.
18. Bugert P, Dugrillon A, Gunaydin A, Eichler H, Kluter H. Messenger RNA profiling of human platelets by microarray hybridization. Thromb Haemost 2003; 90: 738-48.
19. Bugert P, Kluter H. Profiling of gene transcripts in human platelets: an update of the platelet transcriptome. Platelets 2006; 17: 503-4.
20. McRedmond JP, Park SD, Reilly DF, Coppinger JA, Maguire PB, Shields DC, Fitzgerald DJ. Integration of proteomics and genomics in platelets: a profile of platelet proteins and platelet-specific genes. Mol Cell Proteomics 2004; 3: 133-44.
21. Kienast J, Schmitz G. Flow cytometric analysis of thiazole orange uptake by platelets: a diagnostic aid in the evaluation of thrombocytopenic disorders. Blood 1990; 75: 116-21.
22. Kieffer N, Guichard J, Farcet JP, Vainchenker W, Breton-Gorius J. Biosynthesis of major platelet proteins in human blood platelets. Eur J Biochem 1987; 164: 189-95.
23. Amisten S, Braun OO, Bengtsson A, Erlinge D. Gene expression profiling for the identification of G-protein coupled receptors in human platelets. Thromb Res 2008; 122: 47-57.
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001; 25: 402-8.
25. Brull DJ, Sanders J, Rumley A, Lowe GD, Humphries SE, Montgomery HE. Impact of angiotensin converting enzyme inhibition on post-coronary artery bypass interleukin 6 release. Heart 2002; 87: 252-5.
26. Okubo N, Hatori N, Ochi M, Tanaka S. Comparison of m-RNA expression for inflammatory mediators in leukocytes between on-pump and off-pump coronary artery bypass grafting. Ann Thorac Cardiovasc Surg 2003; 9: 43-9.
27. Ekstrom M, Halle M, Bjessmo S, Liska J, Kolak M, Fisher R, Eriksson P, Tornvall P. Systemic inflammation activates the nuclear factor-kappaB regulatory pathway in adipose tissue. Am J Physiol Endocrinol Metab 2010; 299: E234-40.
28. Roffi M, Mukherjee D. Platelet glycoprotein IIb/IIIa receptor inhibitors - end of an era? Eur Heart J 2008; 29: 429-31.
29. Steiner M, Baldini M. Protein synthesis in aging blood platelets. Blood 1969; 33: 628-33.
30. Thon JN, Devine DV. Translation of glycoprotein IIIa in stored blood platelets. Transfusion 2007; 47: 2260-70.
31. Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, Theurl I, Widder W, Molnar C, Ludwiczek O, Atkins MB, Mier JW, Tilg H. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood 2001; 98: 2720-5.
32. Zimmermann N, Wenk A, Kim U, Kienzle P, Weber AA, Gams E, Schror K, Hohlfeld T. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003; 108: 542-7.
33. Matthai WH Jr. Thrombocytopenia in cardiovascular patients: diagnosis and management. Chest 2005; 127(Suppl 2): 46S-52S.
34. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367: 606-17.
35. Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 1996; 7: 157-61.
36. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes. Lancet 2000; 355: 337-45.
37. O'Neill WW, Serruys P, Knudtson M, van Es GA, Timmis GC, van der Zwaan C, Kleiman J, Gong J, Roecker EB, Dreiling R, Alexander J, Anders R. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE trial investigators. Evaluation of oral xemilofiban in controlling thrombotic events. N Engl J Med 2000; 342: 1316-24.
38. Funk CD, Funk LB, Kennedy ME, Pong AS, Fitzgerald GA. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J 1991; 5: 2304-12.
39. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28: 1702-8.
40. Zimmermann N, Kienzle P, Weber AA, Winter J, Gams E, Schror K, Hohlfeld T. Aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2001; 121: 982-4.
41. Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schror K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999; 353: 900.
42. Brambilla M, Parolari A, Camera M, Colli S, Eligini S, Centenaro C, Anselmo A, Alamanni F, Tremoli E. Effect of two doses of aspirin on thromboxane biosynthesis and platelet function in patients undergoing coronary surgery. Thromb Haemost 2010; 103: 516-24.
43. Bigalke B, Kramer BF, Seizer P, Fateh-Moghadam S, Gawaz M, Lindemann S. Diagnostic and therapeutic potentials of platelet glycoprotein VI. Semin Thromb Hemost 2010; 36: 203-11.